It has also been shown that SCH23390 exerts a direct inhibitory effect on IL-17, IFN-γ, and GM-CSF production by anti-CD3 and anti-CD28-activated CD4+ T cells in relapsing–remitting MS patients, while sulpiride has no effect on cytokine production [37]. Here, IL17A is linked to myeloid sarcoma.